Greenwich LifeSciences (GLSI) Other financing activities (2024 - 2025)

Greenwich LifeSciences (GLSI) posted Other financing activities of $145000.0 for Q3 2025, down 94.44% on a QoQ basis from $2.6 million in Q2 2025.

Greenwich LifeSciences (GLSI) Other financing activities (2024 - 2025) Analysis & Trends

Greenwich LifeSciences' Other financing activities history runs 2 years deep, the most recent figure standing at $145000.0 for Q3 2025.

Quarterly Other financing activities changed N/A year-over-year to $145000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $3.2 million (up 73.65% YoY) and the FY2025 annual result came in at $145000.0, down 92.24% from the prior year.
Other financing activities was $145000.0 for Q3 2025 at Greenwich LifeSciences, down from $2.6 million in the prior quarter.
Across five years, Other financing activities topped out at $2.6 million in Q2 2025 and bottomed at -$630887.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Greenwich LifeSciences	178.53 Mn	178.53 Mn	-

Download Data